Talphera Welcomes Joe Todisco to Board, Signaling Growth and Strategic Collaboration

Strategic Board Appointment Signals Growth for Talphera, Inc.

Talphera, Inc., a notable player in the specialty pharmaceutical sector, announces the appointment of Joe Todisco, CEO of CorMedix Inc., to its Board of Directors. This strategic move comes on the heels of CorMedix's investment in Talphera, made during a private placement financing in September 2025. Through this investment, CorMedix secures the right to nominate a board representative, underscoring its commitment to Talphera's future. The appointment is significant as it aligns with Talphera’s ambitious goals, particularly regarding the development and commercialization of its lead product, Niyad™.

Niyad™, a lyophilized formulation of nafamostat, is currently under investigation as an anticoagulant for extracorporeal circuits. The product has garnered attention for its potential to revolutionize treatment protocols in medically supervised settings, especially in continuous renal replacement therapy (CRRT). The FDA has granted Niyad™ Breakthrough Device Designation, indicating its potential to significantly improve patient outcomes. The ongoing NEPHRO CRRT clinical study is crucial, as positive primary endpoint results could pave the way for a potential acquisition agreement with CorMedix, reflecting a shared vision for advancing patient care.

Adrian Adams, Chairman of Talphera’s Board, expresses confidence in Todisco's extensive pharmaceutical expertise, especially concerning commercialization strategies and product portfolio expansion. This partnership is poised to enhance Talphera’s capacity to introduce innovative therapies to the market. With the registrational NEPHRO CRRT study on the horizon, the company remains optimistic about Niyad™'s prospects for approval in 2026. Talphera is strategically positioned at the intersection of cutting-edge research and practical healthcare solutions, aiming to set a new standard of care in its field.

In addition to the board appointment, the collaboration with CorMedix is expected to provide Talphera with the resources and strategic guidance necessary for growth. This relationship not only strengthens Talphera's development pipeline but also highlights the increasing interest in innovative treatments for critical medical conditions. The company’s commitment to advancing therapies for medically supervised environments suggests a proactive approach to addressing unmet clinical needs.

As Talphera continues to navigate the complexities of drug development and regulatory approvals, its partnership with CorMedix may serve as a catalyst for future innovations in the pharmaceutical landscape. For more information about Talphera and its initiatives, interested parties can visit their website at www.talphera.com.